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1. Introduction
Over the last 30 years, upper gastrointestinal endoscopy has become the investigation of
choice for patients with symptoms referable to upper gastrointestinal tract. Owing to the
increasing  number  of  patients  who should be  undergone endoscopy with  a  consequent
high  cost  and  a  marked  workload  and  medical  expenses  for  the  hospitals,  it  has  been
recommended that pre-endoscopy screening strategies might identify patients at low risk
of  having  major  pathology.  These  patients  could  avoid  prompt  endoscopy  and  might
safely undergo different management.
Considering that Helicobacter pylori (Hp) is the most frequent aetiologic agent in these pathol‐
ogies, several invasive and non-invasive diagnostic tests have been taken into account for the
diagnosis of Hp in the individual patient. The non-invasive tests obviate the need for endos‐
copy and can be surely more accepted by the subjects.
It has been proposed [1,2,3] that younger patients with symptoms of dyspepsia with non-
alarming symptoms could be screened non-invasively for the infection in order to reduce
endoscopy procedure. In addition, non-invasive tests are suitable, other than for pre-endos‐
copy screening of younger dyspeptics, also for use in research and for epidemiological surveys
as well as for confirming successful eradication after treatment and for screening asympto‐
matic population.
The pre-endoscopy screening is based on different methodologies (such as serological markers,
molecular markers, etc.) that will be discussed in the present chapter.
© 2013 Mascellino et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Serological markers
Serological testing has been recommended for initial pre-endoscopy or pre-treatment screen‐
ing in dyspeptic patients. Serology is cheap and convenient and thus should be preferred in
situations where the additional information yielded by an endoscopy is not needed.
Patients are prone to undergo this analysis because it only requires a simple peripheral blood
collection for the investigation of anti-Hp IgG, IgM and IgA antibodies. The presence of even
high levels of immunoglobulines does not appear to influence eradication of the bacteria from
the stomach: the microorganism in fact is rarely eliminated and when it is not treated ade‐
quately, the infection generally persists in the rest of an individual’s life [4].
For these reasons, the use of serological tests are very commonly used for clinically diagnosis
of Hp-related infections. In general, the serum levels of anti-H. pylori IgG antibodies increase
in the presence of infection and can be used as a marker. On the other hand, even if anti-Hp
IgA antibodies are less appropriate for this purpose [5], serological findings of anti-Hp IgA in
symptomatic patients might have significant clinical value for the diagnosis of infection,
especially if the patient is seronegative for IgG. The disadvantage for serology is that past or
current infections are not distinguished owing to the fact that past infections may lead to false
positive, so that this test cannot be used for determining therapy success after treatment even
if successful eradication can follow a substantial drop in antibody title, using repeat serology
after a delay post-treatment. [6]
2.1. Serology as diagnostic tool
Serological testing is recommended for initial pre-endoscopy or pre-treatment screening in
dyspeptic patients. The systemic response typically comprises a transient rise in IgM followed
by a rise in specific IgA and IgG maintained throughout infection.
The consideration that patients with IgG antibodies to Hp have a greater risk of peptic ulcer
disease as a cause of their dyspepsia, has led to screen dyspeptic patients under the age of 45
years using Hp serology. Three strategies are proposed after serology screening:
1. endoscopy of Hp seropositive patients and treatment of seronegative patients sympto‐
matically;
2. treatment of seropositive patients for Hp and endoscopy of seronegative patients
3. eradication of infection from Hp seropositive patients, treatment of seronegative patients
symptomatically and endoscopy for those with recurrent dyspepsia.
The attitude in both gastroenterologists and general practitioners with interest in gastroen‐
terology towards the current pattern of use of pre-endoscopic Hp serology screening of young
dyspeptics has been evaluated [7].
The most popular strategy among general practitioners is that of eradicating infection from
seropositives and treating seronegatives symptomatically. In contrast, the most popular
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strategy among gastroenterologists is that of endoscoping seropositives and treating seroneg‐
atives symptomatically.
There is then wide variation in attitudes and practice between these two groups: general
practitioners like more serological tests and strongly prefer eradicating infection in seroposi‐
tives before addressing to endoscopy (even for cost consideration). On the contrary, the
majority of gastroenterologists would endoscope seropositives before treating the infection.
In any case, it is recommended that non-invasive Hp testing should be used in place of
endoscopy with all those testing positive being given anti-Hp therapy and those testing
negative being treated symptomatically. The above strategy of “test and treat” used in clinical
practice may include some inconveniences: expense morbidity from drug side effects and
introduction of antibiotic resistance both in Hp and in other pathogens [8].
An important serological tool for the pre-endoscopy screening in patients at risk of carcinoma
includes the quantitative determination of the different subclasses of IgG. In fact, a selective
reduction of anti-Hp IgG subclass antibody is proven to occur in gastric carcinoma [9]. Cell-
mediated immunity influences the outcome of infection including the development of gastric
carcinoma (CG). The T-cell response comprises a secreted cytokine profile which influences
the B-cell response including the production of the different IgG subclass antibody. In the
adenocarcinoma, a fall in IgG level is demonstrated resulting to be particularly predictive of
cancer [10]. This is thought to reflect premalignant gastric atrophy with loss of colonization
and antigens stimulus [11]. A diminuished IgG antibodies response due to low immunoge‐
nicity of Hp-LPS or to the loss of Hp in some subjects evolving to GC, could reflect the
premalignant phase of gastric atrophy. Significantly lower IgG2 levels are found in subjects
with gastric carcinoma compared with those with reflux oesophagitis, chronic gastritis, gastric
ulcer and peptic ulcer whereas IgG1 antibody remains at similar levels (Figure1). The levels
of IgG 3 and IgG 4 are not affected and in most subjects are undetectable. The decreasing of
IgG 2 subclass level, noticed in patients with adenocarcinoma and not in other Hp-related
pathologies, depends on both the switching of mucosal cytokine secretion and the different
kinetics of IgG response to gastric colonization by B-lymphocyte that can be influenced by
cytokine profiles in secreting different antibody patterns.
Consequently, the patients showing low levels of IgG especially of subclass IgG 2 (below an
established cut-off value) can be considered subjects at high risk of developing pre-malignant
disease, gastric atrophy and adenocarcinoma [9]. These data show that above certain levels of
antibody, irrespective of age, the risk of cancer is low and that primary endoscopy could be
restricted to those with antibodies values below this level. In this way, the endoscopy could
be avoided, as initial investigation, in 42% of dyspeptic subjects [9].
The value of this test as a predictive diagnostic tool in the pre-endoscopy screening strategy
is crucial.
In conclusion, the screening strategy based on Hp serological status, determined with the
enzyme-linked immunoadsorbent assay (ELISA) and Western blotting (WB), in patients with
uncomplicated, simple dyspepsia up to 55 years of age, is able to identify 95%-100% of patients
with significant gastroduodenal lesions while potentially saving 47% of endoscopies [12].
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2.2. Sensitivity and specificity of serological test
The concentration of serum IgG is reported to have sensitivity of 64%, specificity of 83.7 %,
PPV (Positive Predictive Value) of 82%, NPV (Negative Predictive Value) of 66% and accuracy
of 73.1% for the diagnosis of Hp infection [4]. For the same purpose, serum IgA has the
following values: 72.0%, 65.9%, 72.0%, 64.4% and 69.8% respectively [4]. If the serological tests
are considered together (when both test are positive or negative), some of these values could
increase: the accuracy could be 80%, sensitivity 86.6%, specificity 74.2%, PPV 74.2 % and NPV
86.6%. In synthesis, the serological tests are efficient in the diagnosis of the presence or absence
of Hp infection and when used simultaneously, they are more efficient in accuracy, sensitivity
and negative predictive value than when used alone. (Table 1)
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
IgG alone 64 83.7 82 66 73.1
IgA alone 72 65.9 72 67.4 69.8
IgG + IgA (both
positive or negative) 86.6 74.2 74.2 86.6 80
Modified from A. Locatelli et al. (2004)
Table 1. Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value(NPV), Accuracy of IgG and
IgA detection in serum.
Serum Helicobacter pylori-specific 
IgG1 and IgG2 antibody in subjects 
w ith Gastric Cancer (GC), Duodenal 
U lcer (DU), Chronic Gastritis (CG) and 
Reflux Esophagitis (RE)
0
200
400
600
800
1000
GC DU CG RE
E
li
s
a
 
U
n
it
IgG1
IgG2
Figure 1. Serum Helicobacter pylori-specific IgG1 and IgG2 antibody in subjects with Gastric Cancer (GC), Duodenal
Ulcer (DU), Chronic Gastritis (CG) and Reflux Esophagitis (RE)
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The detection of Hp IgA and IgG antibodies in serum is useful in distinguishing between
infected and uninfected patients whereas the concentration of antibodies in duodenal fluid is
not suitable at this purpose [13]
2.3. Advantages and disadvantages
Screening strategies, based on the serology used as marker of virulence, surely results to be
very useful as reported above. The main advantage of serology is that it is a non-invasive and
simple method for diagnosing Hp infections and for screening individuals at high risk to
develop malignant disease. Furthermore, it reduces endoscopies taking also into account the
patient’s compliance. A drawback of using serology as predictive diagnostic marker of disease
is that it could miss a proportion (even if irrelevant) of severe pathologies and underlying
malignancy. However, in western countries, this is rare in patients less than 55 years of age
presenting with dyspepsia in the absence of sinister symptoms [14].
3. Molecular markers
Knowing in advance if a Hp strain in a specific patient is virulent or not is vital for the approach
that the clinician should have towards the infected individuals. In other words, the presence
of virulence determinants (such as CagA, VacA, Hsp60 proteins ) can address the gastroen‐
terologists to a correct and suitable therapy. For this aim, strain typing could be generally
useful in pre-endoscopy screening; for example endoscopy might be unnecessary in young
dyspeptic patients without severe symptoms who are infected with non- virulent strains. It
would be better not only to treat young dyspeptic patients infected with virulent strains
without performing an endoscopy but also to treat patients likely to develop ulcers or gastric
malignancy before those conditions arise.
In consequence of this, it would seem preferable to screen for and treat only strains which are
known to cause disease. For this purpose, the serology towards the virulence determinants
can be used instead of invasive endoscopy.
3.1. Vac–A and Cag–A
VacA serology is uncommon because there are some uncertainties about its interpretation
owing to the mosaicism of antigens and to the variety of existing subtypes which are correlated
to the different diseases (for example vacA s1 strains are more commonly associated with ulcer
than vacA s1b strains or vacA s2). In this situation, the vacA genotype should be determined
but that requires a gastric biopsy so vacA genotyping cannot be used in non-invasive screening
strategies.CagA serology is more reliable than VacA serology due to the strong immunoge‐
nicity and the less variability of CagA protein respect to VacA.
CagA seropositivity reflects the presence of cagA gene together with the cag PAI (pathoge‐
nicity island). Some problems linked to CagA serology could occur. First of all, the infection
with CagA+ strains is common so that treating CagA seropositive subjects might result in
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unnecessary treatment even if it has been demonstrated [15] that people with CagA seropos‐
itive infection are at higher risk of ulcers or more severe pathologies than CagA-negative
subjects.
A second problem concerns the fact that avoiding treatment for CagA-negative patients would
lead to miss some infected individual patients who later develop malignancy.
Third the presence of CagA-negative strains may be rare in some populations depending on
geographical area. Further, it would be advisable to know, in CagA-negative subjects, if their
risk of developing more severe disease such as carcinoma is higher than in uninfected people.
If any significant risk is confirmed between CagA-negative infected and uninfected individ‐
uals, the treatment of CagA-negative patients would be strongly recommended.
In synthesis, if there is evidence that treatment of CagA-positive patients reduces the possi‐
bility of subsequent Hp-related malignancy, CagA serology can be considered a viable test for
selecting strains to treat [16, 17].The Hp infectious status is determined serologically using a
commercially available enzyme-linked immunosorbent assay ELISA with a sensitivity and
specificity of 96% and confirmed by Western blotting (WB).
3.2. Hsp60 (Heath schock protein 60)
Antibodies to Hsp60 have been suggested as markers of chronic inflammation so the detection
of anti-Hsp60 covers a crucial role as serological marker of strain-virulence and may therefore
be good predictors for the risk of vascular diseases as well as it has been reported for Chlamydia
species [18]. High levels of anti-Hsp60 antibodies may constitute a marker and/or a concomi‐
tant pathogenic factor of these pathologies.
Lenzi C et al, 2006 [19] found an increased prevalence of CagA-positive Hp infection as well
as increased levels of antibodies to Hsp60 in patients with CHD (Coronary Heart Disease)
compared with controls. The accurate definition of this new risk factor may lead to novel
strategies for the prevention of ischemic heart disease since simple procedures such as the
detection of anti-Hsp60 may be a good predictor of ischemic illness.
Wick et al [20] demonstrated that the association between high levels of anti-Hsps60 antibodies
and atherosclerotic vascular disease is due to an autoimmune reaction to endothelial cells that
express high levels of Hsps in response to different stimuli such as free radicals, local infections,
cytokines etc.
Antibodies to Hsp60 are determined by ELISA test using a commercially available human
hsp60 (Sigma Che. Co., Milan, Italy) (19).
4. Multiplex PCR assay (Molecular screening)
The molecular markers of virulence, listed above, can be easily detected, other than by the evi‐
dence of antibodies towards them through the serology, also by multiplex assays based on PCR.
Multiplex PCR assay is an advancement, compared to uniplex or single locus PCR, because it is
suited to diagnose and specifically identify virulence Hp strains and their main virulence genes
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cagA, cagE, cagT, vacA, hrgA. This method is able to genotype Hp isolates based on the main
virulence genes analysis of cagA alleles as well as vacA is performed by polymerase chain reac‐
tion (PCR). The methodology for performing Multiplex PCR is reported by Tiwari et al. 2007
[17]. Briefly, samples in sterile phosphate bufferd saline after being vortexed, are boiled, cooled
in ice and centrifuged. The supernatant is transferred to another tube where 1 μl of the tem‐
plate for amplification is added. Multiplex PCR is carried out in 25-μl volumes using DNA, Taq
polymerase, oligonucleotide primers of all the selected genes, deoxynucleotide triphosphate
and MgCl2 in standard PCR buffer for 35 cycles.
PCR products are electrophoresed in agarose gel with ethidium bromide in a Tris-borate-
EDTA buffer. Gel is visualized under UV transilluminator. Polymerase chain reaction products
of each target genes are sequenced directly after purification.
The PCR products were inspected by eletrophoresis on 2% agarose gels. Reference strain H.
pylori ATCC 49503 is used as a positive control whereas water for cell culture grade was used
as negative control. [21].
This method results very useful in distinguishing five potential virulence genes also including
the two subtypes of vacA signal region (s1 and s2). This new strategy, which not only predicts
mere presence or absence of Hp infection but also gives information about its genetic hetero‐
geneity, is highly recommended especially because it is a fast and reliable alternative to others
methods and also can be employed even in highly contaminated samples. Different genotypes
are reported to be correlated to various infection kind by Tiwari et al. 2007 [17].
In this study, they report the distribution of the above genes in the different pathologies
(Table 2).
Gastric
carcinoma Duodenal ulcer
Pre-pyloric
ulcer Peptic ulcer GERD* NUD**
% % % % % %
vacA s1 85 64 100 100 50 50
vacA s2 14 35 / / 50 50
cagA 100 78 100 50 100 66
cagE 100 85 100 100 100 83
cagT 100 92 100 100 100 83
hrgA 100 100 100 100 100 100
Modified from S.K. Tiwari et al. (2007)
GERD* : Gastric oesophageal reflux disease; NUD**: Non-ulcer disease
Table 2. Distribution of major virulence genes of Helicobacter pylori in various diseases.
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An important finding of this study is that hrgA gene results to have 100% prevalence among
all disease groups irrespective of clinical category. This result differs from that obtained by
Ando 2002 [22] who reported a more marked presence of hrgA in patients with cancer than in
those with other pathologies. These discordant data can depend on different geographical
areas considered in the two researches and on the need of examining a more large number of
subjects. Higher prevalence of the genotype cagT +, hrgA +, cagA +, cagE + and vacAs1 + is
found among patients with pre-pyloric ulcer (100%) and gastric carcinoma (85.7%) followed
by duodenal ulcer subjects (60.7%). Overall, this genotype is present in 67% of the total subjects
analysed with higher occurrence among those with ulceration and gastric carcinoma than
among those with GERD (gastric oesophageal reflux disease) and NUD (non-ulcer disease).
The genotype cagT +, hrgA +, cagA-, cagE + and vacAs2 subtype is least prevalent. The vacAs1
subtype is more correlated with the presence of cagA than the vacAs2 subtype and only 2.44%
CagA-negative strains possess the vacAs1 allele. Then with reference to the clinical status,
vacAs1 is prominent in patients with pre-pyloric ulcer (100%), gastric carcinoma (85%) and
duodenal ulcer (64%).However, this study has been performed using gastric tissues (biopsies).
Consequently it is an invasive method and cannot be used as a pre-endoscopy screening. The
same authors in a previous attempt, had reported saliva as one of the effective non-invasive
specimen not only for the detection of Hp infection but also for genotyping the strain infecting
[23]. The 16S rRNA gene of Hp is a highly specific target for amplification, able to confirm Hp
infection. Positive amplification of Hp specific DNA may be considered as a direct evidence of
the presence of the pathogen. Non-invasive methods for the rapid diagnosis of Hp in salivary
secretion of patients with various gastric diseases using 16S rRNA PCR analysis result to be
very useful in pre-endoscopy screening thus showing comparable results with those obtained
when biopsies are used (Table 3).Consequently saliva of infected persons serves as a reliable
non-invasive alternative to detect the presence of Hp infection compared to currently diag‐
nostic invasive tests. Tiwari et al [24] in another research also report salivary secretion as a
sample suitable for detecting cag PAI (pathogenicity island) of infecting Hp correlating this
with the disease status of the patients. Hence, analysis of complete cag PAI of H. pylori isolated
from saliva would be of immense importance in standardizing saliva as a reliable non-invasive
diagnostic specimen and also to evaluate the type of Hp infection. cagE and cagT are found in
a larger proportion of the ulcer group than in the non-ulcer group [24,25].
Symptomatic subjects Asymptomatic subjects
(80) (20)
N° % N° %
Stomach biopsy 72 (90) 10 (50)
Saliva 70 (87.5) 12 (60)
Modified from S.K. Tiwari et al. (2005)
Table 3. Detection of H. pylori in biopsies and in salivary secretions by multiplex PCR.
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5. Multiplex bead array assay and pre–endoscopy screening
A number of new methodologies and assays have been defined during the last years in order
to have reliable, rapid, precise and cost-effective results for the management of many diseases.
Furthermore, these methods include the use of non-invasive specimens such as serum and
plasma being then a useful tool for pre-endoscopy screening. Multiplex bead array assays
(MBAA) and Luminex X-map constitute an advancement in detecting contemporaneously bio-
markers in plasma and serum. They result comparable to ELISA method and in addition have
the advantage of revealing, independently and quantitatively, a large number of analytes using
an automated 96-well plate format. These methods also permit the molecular study of genetic
variables involved in virulence mechanisms of important bacterial strains.
The clinical applications of MBAA are reported in Table 4.
Application Available kits*
Autoimmune ASCA (h), β-2 Microglobulin (h,m) Centomere B (h)
Cancer markers α-Fetoprotein (h), Cancer antigen 125 (h), Carcinoe
Cytokine Aβ40 (h), Aβ42 (h), BDNF (h) DR-5 (h), EGF (h,m)
Gene expression 1L6R (h), ACTB (h), BAD (h), BAK1 (BAK) (h), BCL
Genotyping FlexMAP (G), Mitochondrial DNA Screening (h)
* (h)= human, (m)= mouse
Modified from F.M. Elshai et al. (2006)
Table 4. Principal clinical applications of MBBA.
The most important application of this test is the quantitative detection of cytokines. The
measurement of soluble cytokines and other analytes plays a pivotal role in Hp-related
infections. In fact, in Hp diseases, a number of pro-inflammatory cytokines such as tumor
necrosis factor-α (TNF- α), interleukin-1β (IL-1β), IL-6, IL-8, IL-2, IL-24 etc, is on the basis of
the host immune response and of the immunopathology of this microorganism. Practically
multiplex assays rely upon the determination of soluble analytes in serum or plasma through
the utilization of specific beads for each ligand with subsequent detection of the captured
ligand by a second “reporter” antibody. Positive reaction is detected by the fluorescences
where ELISA method uses enzyme amplification of a colorimetric substrate.
Protein microarray kits that use capture antibodies in a multiplex fashion similar to MBAA,
are relatively new but they are not accepted as a “gold standard” for clinical use and may be
of limited sensitivity [26].
Problems for the MBAA technique can arise for the multiplex nature of the test that can lead
to cross-reactions and to anomalies in quantifying some analytes. Interferences can also occur
in anti-cytokine antibodies which may cross-react whit other cytokines and other interfering
Pre–Endoscopy Screening of Helicobacter pylori Infection: Implication and Advantages
http://dx.doi.org/10.5772/52734
31
substances. Kits have been optimized to eliminate or minimize any artefact from multiplexing.
Nevertheless the problem of interferences can exist.
Test ELISA has been considered as a “gold-standard” for the determination of the analytes in
plasma and serum but MBAA test is comparable to it [27]. Even if these two tests have been
correlated in many studies [26, 27], it can be difficult to evaluate the results because various
investigators use different methods of comparison between MBAA and ELISA. Most of
published studies [28,29] have shown good correlation and reproducibility between these two
methodologies for the majority of cytokines tested even if the degree of correlation has varied
widely. MBAA test has proven to be easy to perform, reliable, time saving and cost-effective
so that its use in the clinical practice and in the research area is suggested. (27)
6. Luminex X–MAP technology
Among various MBAA tests that generally incorporate an automatic software able to evaluate
the cytokine levels in the samples (plasma and serum), significantly reducing the complexity
of the assay and requiring less user interaction, Luminex X-MAP technology plays an impor‐
tant role. It uses digital signal processing capable of classifying polystyrene beads (micro‐
spheres) dyed with distinct proportion of red and near-infrared fluorophores.
A spectral address for each bead population can be defined by these proportions. In this case,
different detection reaction can be carried out simultaneously on various bead populations.
Some recent applications with Luminex-based fluorescent microspheres include cytokine
quantitation [30] and polymorphism genotyping [31]. In conclusion we can say that it is
possible to measure, with these new methodologies, the level of important cytokines involved
in Hp immunopathology. These results can make us know, through non-invasive methods,
the pattern of cytokines involved in the infection which accounts for the disease status and the
strain virulence.
7. Conclusions
The non-invasive tests as diagnostic tool in Hp infections of patients with various gastrointes‐
tinal disorders, are strongly important because they make the endoscopy unnecessary in
different situations. The pre-endoscopy screening may be performed principally through
serological markers (detection of different kinds of immunoglobulines) or through molecular
markers (presence of CagA or Hsp60).
For CagA detection, serology has proved to be useful, being CagA protein a factor with good
antigenic properties, easy and realiable to perform and prone to reveal the presence of Cag
pathogenicity island [12]. Hsp60 is also a good antigen so that its detection can be performed
through the appearance of specific antibodies against it.[32]
Strain typing could also be useful in pre-endoscopy screening: in fact the invasive gastroscopy
could be avoided in young populations with non-ulcer dyspepsia and with non-alarming
Endoscopy of GI Tract32
symptoms. It might be even better to treat patients infected with virulent strains without
performing an endoscopy. For these problems, the fact to know in advance if a Hp strain is
virulent or not, could allow us to treat only isolates with proved aptitude to cause disease.
What we would suggest concerns the rapid and easy detection of virulent strains avoiding
both invasive techniques and the consequences of a long-lasting untreated infection. The best
approach for this is the new development of multiplex PCR assay considered an advancement
over other PCR-based methods which could contribute to gain insights at the genotypic
variability exhibited by this pathogen. Multiplex PCR assay by which the presence of various
markers can be detected in a single reaction constitutes an important tool [17].
Other new methods such as new multiplex assays (Multiplex Bead Array Assays-MBAA) and
Luminex-X map technology, constitute a considerable advancement for genotyping Hp thus
using non-invasive samples as serum, plasma and salivary secretions [26, 27].
Further problems that should be more deeply examined concern the possible link that may
exist between strains with more combinations of virulence determinants and antibiotic
resistance that is known to be a crucial drawback in the disease treatment.
Author details
Maria Teresa  Mascellino1*, Alessandra  Oliva1 and Barbara  Porowska2
*Address all correspondence to: mariateresa.mascellino@uniroma1.it
1 Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
2 Department of General and Specialistic Surgery, “Paride Stefanini”, Sapienza University,
Rome, Italy
References
[1] Censini S., Lange C., Xiang Z.Y. et al. CagA pathogenicity island of Helicobacter pylori,
encoder type I-specific and disease associated virulence factors. Proc Natl Acad Sci USA,
1996;93: 14648-14653.
[2] Center for Disease Control. Universal precaution for prevention of transmission of
human himmunodeficiency virus, hepatitis B virus and other bloodborne pathogens
in healt-care settings.United States Morbid Mortal Weekly Rep 1988;37:377-382, 387-388.
[3] Corrado E., Novo S.. Role of inflammation and infection in vascular disease. Acta Chir
Belg 2005; 105 :567-579.
Pre–Endoscopy Screening of Helicobacter pylori Infection: Implication and Advantages
http://dx.doi.org/10.5772/52734
33
[4] Locatelli A., Catalani W.R., Gomes Junior C.R., Battistin C., Paula Silva, Waisberg J..
Detection of Anti-Helicobacter pylori antibodies in serum and duodenal fluid in peptic
gastroduodenal disease. World J Gastroentreol 2004; 10:2997-3000.
[5] Andersen L.P., Kiilerick S., Pedersen G., Thoreson A.C., Jorgensen F., Rath J., Larsen
N.E., Borup O., Krogefelt K., Scheibel J., Rune S.. An analysis of seven different methods
to diagnose Helicobacter pylori infections. Scand J Gastroenterol 1998; 33: 24-30.
[6] Kosunen T.U., Hook J., Rautelin H.I., Myllyla G.. Age dependent increase of Campylo‐
bacter pylori antibodies in blood donors. Scand J Gastroenterol 1989;24: 110-114.
[7] Lim A.G. , Martin R.M., Monteleone M., Walker A.C., Gould S.R.. Helicobacter pylori
serology and the managment of young dydpeptics: a UK survey of gastroenterologists
and general practitioners with an interest in gastroenterology. Aliment Pharmacol Ther
1997; 11: 299-303.
[8] Atherton J.C. H. pylori virulence factors. British Medical Bulletin 1998; 54: 105-120.
[9] Ren Z., Borody T., Pang G., Chen Li L., Dunkley M., Clancy R. Selective reduction of
Anti-Helicobacter pylori IgG Subclass Antibody in Gastric Carcinoma. Journal of Gastro‐
enterology and Hepatology. 2005; 20:1338-1345.
[10] Tulinius H., Ogmundsdottir H.M., Kristinsson K.G. et al. Helicobacter pylori antibodies
and gastric cancer in Iceland: the decline in IgG antibody level is a risk factor. APMIS
2001; 109:835-841.
[11] Correa P. Human gastric carcinogenesis:a multistep and multifactorial process- first
American Cancer Society Award Lecture on cancer epidemiology and prevention.
Cancer Res 1992; 52:6735-6740.
[12] Bodger K., Wyatt J.L., Heatley R.V. Serologic screening before endoscopy: the value of
Helicabacter pylori serology, serum recognition of the CagA and VacA proteins, and
serum pepsinogen I. Scand J Gastroenterol 1999; 34:856-863.
[13] Mc Nulty C.A., Nair P., Watson B.E., Uff J.S., Valori R.M. A comparison of six com‐
mercial kits for Helicobacter pylori detection. Commun Dis Public Health 1999;1: 59-63.
[14] Mc Coll K. Should non-invasive Helicobacter pylori testing replace endoscopy in
investigation of dydpepsia? Helicobacter 2000;5: 11-31.
[15] Blaser M.J., Pèrez-Pèrez G.I., Kleanthas H. et al. Infection with Helicobacter pylori strains
possessing cagA is associated with an increate risk of developing adenocarcinoma of
the stomach. Cancer Res 1995;55: 2111-2115.
[16] Rhead J.L., Letley P.D., Mohammad M., Hussein N., Mohagheghi M.A., Hosseini M.E.,
Atherton J.C.. A new Helicobacter pylori Vacuolating Cytotoxin Determinant, the
Intermediate Region, Is Associated With Gastric Cancer. Gastroenterology 2007;
133.926-936.
[17] Tiwari S.K., Khan A.A., Manoj G., Ahmed S., Abid Z., Habeeb A., Habibullah C.M.. A
simple multiplex PCR assay for diagnosing virulent Helicobacter pylori infection in
Endoscopy of GI Tract34
human gastric biopsy specimens from subjects with gastric carcinoma and other gasto-
duodenal diseases. Journal of Applied Microbiology 2007;103: 2353-2360.
[18] Mascellino M.T., Ciardi M.R., Oliva A., Cecinato F., Borghese L. Chlamydia trachomatis
detection in a population of asymptomatic and symptomatic women: correlation with
the presence of serological markers for this infection. New Microbiologica 2008;31:
249-256.
[19] Lenzi C., Palazzuoli A., Giordano N., Alegente G., Gonnelli C., Campagna M.S.,
Cantucci A., Sozzi M., Papakostas P., Rollo F., Nuti R., Figura N. H pylori infections and
systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart
disease. World J Gastroenterol 2006;48: 7815-7820.
[20] Wick G., Knoflach M., Henderson B., Bernhard D. Heat shock proteins and stress in
atherosclerosis. Autoimm Rev 2004;3: 30-31.
[21] Lozniewski A., Muhale F., Hatier R. et al. Human embryonic gastric xenografts in nude
mice: a new model of Helicobacter pylori infection. Infect. Immun 1999;67: 1798–1805.
[22] Ando T., Wassenaar M., Peek R.M., Aras R.A., Tschumi A.I., van Doorn L.J., Kusugami
K., Blaser M.J. A Helicobacter pylori restriction endonuclease replacing gene, hrgA, is
associated with gastric cancer in Asian strains. Cancer Res 2002;62: 2385-2389.
[23] Tiwari S.K., Khan A.A., Ahmed K.S., Ahmed I., Kauser F., Hussain M.A., Alì S.M., Alvì,
Habeeb A., Abid Z., Ahmed N., Habibullah C.H. Rapid diagnosis of Helicobacter pylori
infection in dyspeptic patients using salivary secretion: a non-invasive approach.
Singapore Med J 2005;5:224-228.
[24] Tiwari SK, Sharma V, Sharma VK, Gopi M, Saikant R, Nandan A, Bardia A, Gunisetty
S, Katikala P, Habeeb MA, Khan AA, HabibullahCM Phylogenetic analysis, based on
EPIYA repeats in the cagA gene of Indian Helicobacter pylori, and the implications of
sequence variation in tyrosine phosphorylation motifs on determining the clinical
outcome. Genet Mol Biol. 2011 ;34(2):280-285.
[25] Tiwari SK, Manoj G, Sharma V, Sivaram G, Saikant R, Bardia A, Sharma VK, Abid Z,
Khan AA, Habeeb MA, Habibullah CM, Kumar BS, Nandan A.Relevance of Helico‐
bacter pylori genotypes in gastric pathology and its association with plasma malon‐
dialdehyde and nitric oxide levels. Inflammopharmacology. 2010 Apr;18(2):59-64. Epub
2010 Feb 9.
[26] Copeland S., Siddiqui J. and Remick D. Direct comparison of traditional ELISAs and
membrane protein arrays for detection and quantification of human cytokines.J
Immunol Methods 2004;284:99-106.
[27] Elshal M.F. and Mc Cay J.P. Multiplex bead array assays: Performance evaluation And
comparison of sensitivity to ELISA. Science Direct 2006;4: 317-323.
[28] Dubois A., Berg D.E., Incecik E.T., Fiala N., Heman-Ackah L.M., Perez-Perez G.I., Blaser
M.J. Transient and persistent infections of non-human primates with Helicobacter
pylori: implications for human disease. Infect Immun 1996;64: 2885-2891.
Pre–Endoscopy Screening of Helicobacter pylori Infection: Implication and Advantages
http://dx.doi.org/10.5772/52734
[29] Hildesheim A., Ryan R.L., Rineart E., Nayak S., Wallace D., Castle P.E., Niwa S. and
Kopp W. Simultaneous measurement of several cytokines using small volumes of
biospecimens. Cancer Epidemiol Biomarkers Prev 2002;11:1477-1484.
[30] de Sager W., Velthuis H.T.E., Prakren J., Kuis W., Rijkers G.T. Simultaneous detection
of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear
cells.Clin Diagn Lab Immunol 2003;1: 133-139.
[31] Keyes K., Mann L., Cox K., Treadway P., Iverson P., Chen Y.F., Teicher B.A.. Circulating
angiogenic growth factor levels in mice bearing human tumors using Luminex
Multiplex technology Cancer Chemother Pharmcol 2003;4:321-327.
[32] Kusters J.G., Van Vliet A.H.M., Kuipers E.J. Pathogenesis of Helicobacter pylori Infection.
Clinical Microbiology Reviews 2006; 19(3): 449-490.
Endoscopy of GI Tract36
